WO2000002522A3 - Anthrax vaccine - Google Patents
Anthrax vaccine Download PDFInfo
- Publication number
- WO2000002522A3 WO2000002522A3 PCT/US1999/015568 US9915568W WO0002522A3 WO 2000002522 A3 WO2000002522 A3 WO 2000002522A3 US 9915568 W US9915568 W US 9915568W WO 0002522 A3 WO0002522 A3 WO 0002522A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- anthrax vaccine
- anthrax
- vaccine
- anthracis
- subjects
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99941953A EP1097212B1 (en) | 1998-07-10 | 1999-07-09 | Anthrax vaccine |
DE69940157T DE69940157D1 (en) | 1998-07-10 | 1999-07-09 | Anthrax-impfstoff |
CA002339355A CA2339355A1 (en) | 1998-07-10 | 1999-07-09 | Anthrax vaccine |
AU55426/99A AU758019B2 (en) | 1998-07-10 | 1999-07-09 | Anthrax vaccine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9241698P | 1998-07-10 | 1998-07-10 | |
US60/092,416 | 1998-07-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000002522A2 WO2000002522A2 (en) | 2000-01-20 |
WO2000002522A3 true WO2000002522A3 (en) | 2000-10-12 |
WO2000002522A9 WO2000002522A9 (en) | 2001-04-05 |
Family
ID=22233100
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/015568 WO2000002522A2 (en) | 1998-07-10 | 1999-07-09 | Anthrax vaccine |
PCT/US1999/015569 WO2000002523A2 (en) | 1998-07-10 | 1999-07-09 | Vaccine against staphylococcus intoxication |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/015569 WO2000002523A2 (en) | 1998-07-10 | 1999-07-09 | Vaccine against staphylococcus intoxication |
Country Status (7)
Country | Link |
---|---|
US (2) | US6632640B1 (en) |
EP (2) | EP1097213B1 (en) |
AT (2) | ATE418612T1 (en) |
AU (2) | AU761021B2 (en) |
CA (2) | CA2339355A1 (en) |
DE (2) | DE69940157D1 (en) |
WO (2) | WO2000002522A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906119B1 (en) | 2002-06-26 | 2011-03-15 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
US7087235B2 (en) * | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
ATE418612T1 (en) * | 1998-07-10 | 2009-01-15 | U S Medical Res Inst Of Infect | ANTHRAX VACCINE |
MXPA01001631A (en) * | 1998-08-13 | 2002-04-08 | Walter Reed Army Inst Of Res D | Bacterial superantigen vaccines. |
WO2000062856A1 (en) | 1999-04-16 | 2000-10-26 | Johnson & Johnson Consumer Companies, Inc. | Drug delivery device comprising a dual chamber reservoir |
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
GB0016702D0 (en) | 2000-07-08 | 2000-08-23 | Secr Defence Brit | Expression system |
SE0102327D0 (en) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
GB0118009D0 (en) * | 2001-07-24 | 2001-09-19 | Regma Biotechnologies Ltd | Novel preparation |
CA2460269C (en) * | 2001-09-06 | 2013-01-15 | Alphavax, Inc. | Alphavirus replicon vector systems |
JP2005511059A (en) | 2001-12-05 | 2005-04-28 | バートナガー ラケシュ | Process for the preparation of non-toxic anthrax vaccine |
WO2003087378A1 (en) * | 2002-04-11 | 2003-10-23 | Powderject Research Limited | Nucleic acid immunization |
US20070105799A1 (en) * | 2002-09-10 | 2007-05-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
JP4991108B2 (en) * | 2002-12-13 | 2012-08-01 | アルファバックス,インコーポレイティド | Multi-antigenic alphavirus replicon particles and methods |
KR101518309B1 (en) * | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | Improved alphavirus replicons and helper constructs |
WO2005034841A2 (en) * | 2003-05-14 | 2005-04-21 | Merck & Co., Inc. | Anthrax vaccine |
AU2004257214B2 (en) * | 2003-07-11 | 2010-04-22 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
WO2005026203A2 (en) | 2003-09-18 | 2005-03-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dna promoters and anthrax vaccines |
US8409590B2 (en) | 2004-02-11 | 2013-04-02 | Ligocyte Pharmaceuticals, Inc. | Anthrax antigens and methods of use |
US20080095777A1 (en) | 2004-09-22 | 2008-04-24 | Glaxosmithkline Biologicals S.A. | Immunogenic Composition for Use in Vaccination Against Staphylococcei |
BRPI0609362A2 (en) * | 2005-04-11 | 2010-03-30 | Us Gov Health & Human Serv | recombinant adenovirus vector, recombinant adenovirus, immunogenic composition and method for producing said immunogenic composition |
CN101242856A (en) | 2005-09-09 | 2008-08-13 | 莱博法姆公司 | Sustained drug release compositions |
JP2009531387A (en) | 2006-03-30 | 2009-09-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Immunogenic composition |
US20070248960A1 (en) * | 2006-04-19 | 2007-10-25 | Rees Dianne M | Arrays containing cleavable RNAi molecules |
US7850977B2 (en) * | 2007-06-21 | 2010-12-14 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
CA2697538C (en) | 2007-08-31 | 2019-02-12 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
WO2009063507A1 (en) * | 2007-11-12 | 2009-05-22 | Rakesh Bhatnagar | Dna vaccine against anthrax |
US8758765B2 (en) | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
EP2341929B1 (en) | 2008-10-06 | 2017-01-25 | University Of Chicago | Compositions and methods related to bacterial emp proteins |
WO2011005341A2 (en) | 2009-04-03 | 2011-01-13 | University Of Chicago | Compositions and methods related to protein a (spa) variants |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP2555794A4 (en) | 2010-04-05 | 2014-01-15 | Univ Chicago | COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SpA) ANTIBODIES AS AN ENHANCER OF IMMUNE RESPONSE |
AU2011274367B2 (en) | 2010-07-02 | 2015-04-23 | The University Of Chicago | Compositions and methods related to protein A (SpA) variants |
EP2614074A1 (en) | 2010-09-09 | 2013-07-17 | The University of Chicago | Methods and compositions involving protective staphylococcal antigens |
CA2830415A1 (en) * | 2011-03-16 | 2012-12-13 | Regents Of The University Of Minnesota | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
CN103906535B (en) | 2011-08-15 | 2017-07-14 | 芝加哥大学 | The composition related to the antibody of staphylococcal protein A and method |
JP6670106B2 (en) | 2012-04-26 | 2020-03-18 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | Staphylococcal coagulase antigen and method of use |
JP6251730B2 (en) | 2012-04-26 | 2017-12-20 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | Compositions and methods related to antibodies that neutralize coagulase activity during STAPHYLOCOCUSAUREUS disease |
WO2014205111A1 (en) | 2013-06-19 | 2014-12-24 | Integrated Biotherapeutics, Inc. | Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof |
US10314910B2 (en) | 2016-01-10 | 2019-06-11 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy |
US11505722B2 (en) * | 2017-06-30 | 2022-11-22 | The Boeing Company | Nonaqueous sol-gel for adhesion enhancement of water-sensitive materials |
JP7303791B2 (en) | 2017-07-27 | 2023-07-05 | アブヴァク インコーポレイテッド | Immunogenic compositions containing fusion peptides derived from superantigen toxoids |
KR20220009428A (en) | 2019-05-15 | 2022-01-24 | 네오티엑스 테라퓨틱스 엘티디. | cancer treatment |
BR112022005615A2 (en) | 2019-10-02 | 2022-07-12 | Janssen Vaccines & Prevention Bv | STAPHYLOCOCCUS PEPTIDES AND METHODS OF USE |
CN115484978A (en) | 2020-03-05 | 2022-12-16 | 尼奥克斯医疗有限公司 | Methods and compositions for treating cancer using immune cells |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007994A2 (en) * | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
WO1996017067A1 (en) * | 1994-11-30 | 1996-06-06 | Zymogenetics, Inc. | Method for secreting thrombopoietin polypeptides |
WO1996037616A1 (en) * | 1995-05-23 | 1996-11-28 | The University Of North Carolina At Chapel Hill | Alphavirus rna replicon systems |
WO1998008952A1 (en) * | 1996-08-30 | 1998-03-05 | The Secretary Of State For Defence | Vaccine production of the bacillus anthracis protective antigen |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0626805A4 (en) * | 1992-01-28 | 1995-12-06 | Nat Jewish Ct Immun & Respirat | Protective effects of mutated superantigens. |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5705151A (en) * | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
US5935568A (en) * | 1995-05-18 | 1999-08-10 | National Jewish Medical & Research Center | Gene therapy for effector cell regulation |
GB9604045D0 (en) * | 1996-02-26 | 1996-04-24 | Smithkline Beecham Plc | Novel compounds |
US6075119A (en) * | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
US6261570B1 (en) * | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
US6713284B2 (en) * | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
WO1999040935A1 (en) * | 1998-02-15 | 1999-08-19 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Novel preventives/remedies for immunopathy |
US6517842B1 (en) * | 1998-06-29 | 2003-02-11 | The United States Of America As Represented By The Secretary Of The Army | Marburg virus vaccines |
ATE418612T1 (en) * | 1998-07-10 | 2009-01-15 | U S Medical Res Inst Of Infect | ANTHRAX VACCINE |
MXPA01001631A (en) * | 1998-08-13 | 2002-04-08 | Walter Reed Army Inst Of Res D | Bacterial superantigen vaccines. |
AU771774B2 (en) * | 1998-12-07 | 2004-04-01 | U.S. Medical Research Institute Of Infectious Diseases | Live attenuated Venezuelan equine encephalitis vaccine |
-
1999
- 1999-07-09 AT AT99941953T patent/ATE418612T1/en not_active IP Right Cessation
- 1999-07-09 WO PCT/US1999/015568 patent/WO2000002522A2/en active IP Right Grant
- 1999-07-09 CA CA002339355A patent/CA2339355A1/en not_active Abandoned
- 1999-07-09 EP EP99943610A patent/EP1097213B1/en not_active Expired - Lifetime
- 1999-07-09 CA CA002337966A patent/CA2337966A1/en not_active Abandoned
- 1999-07-09 EP EP99941953A patent/EP1097212B1/en not_active Expired - Lifetime
- 1999-07-09 DE DE69940157T patent/DE69940157D1/en not_active Expired - Fee Related
- 1999-07-09 DE DE69941454T patent/DE69941454D1/en not_active Expired - Fee Related
- 1999-07-09 AU AU56673/99A patent/AU761021B2/en not_active Ceased
- 1999-07-09 AU AU55426/99A patent/AU758019B2/en not_active Ceased
- 1999-07-09 AT AT99943610T patent/ATE443768T1/en not_active IP Right Cessation
- 1999-07-09 WO PCT/US1999/015569 patent/WO2000002523A2/en active IP Right Grant
- 1999-07-09 US US09/350,755 patent/US6632640B1/en not_active Expired - Fee Related
-
2003
- 2003-04-02 US US10/405,871 patent/US7374931B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007994A2 (en) * | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
WO1996017067A1 (en) * | 1994-11-30 | 1996-06-06 | Zymogenetics, Inc. | Method for secreting thrombopoietin polypeptides |
WO1996037616A1 (en) * | 1995-05-23 | 1996-11-28 | The University Of North Carolina At Chapel Hill | Alphavirus rna replicon systems |
WO1998008952A1 (en) * | 1996-08-30 | 1998-03-05 | The Secretary Of State For Defence | Vaccine production of the bacillus anthracis protective antigen |
Non-Patent Citations (4)
Title |
---|
IVINS B E ET AL: "CLONING AND EXPRESSION OF THE BACILLUS ANTHRACIS PROTECTIVE ANTIGENGENE IN BACILLUS SUBTILIS", INFECTION AND IMMUNITY,US,AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, vol. 54, no. 2, 1 November 1986 (1986-11-01), pages 537 - 542, XP000650052, ISSN: 0019-9567 * |
L.C. IACONO-CONNORS ET AL.,: "PROTECTION AGAINST ANTHRAX WITH RECOMBINANT VIRUS-EXPRESSED PROTECTIVE ANTIGEN IN EXPERIMENTAL ANIMALS", INFECTION AND IMMUNITY, vol. 59, no. 6, June 1991 (1991-06-01), pages 1961 - 1965, XP000916157 * |
PUSHKO P ET AL: "Replicon-helper systems from attenuated Venezuelan Equine Encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo", VIROLOGY,US,ACADEMIC PRESS,ORLANDO, vol. 239, no. 2, 22 December 1997 (1997-12-22), pages 389 - 401-401, XP002123951, ISSN: 0042-6822 * |
SINGH Y ET AL: "A DELETED VARIANT OF BACILLUS ANTHRACIS PROTECTIVE ANTIGEN IS NON- TOXIC AND BLOCKS ANTHRAX TOXIN ACTION IN VIVO", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 264, no. 32, 15 November 1989 (1989-11-15), pages 19103 - 19107, XP000650160, ISSN: 0021-9258 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906119B1 (en) | 2002-06-26 | 2011-03-15 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
Also Published As
Publication number | Publication date |
---|---|
CA2337966A1 (en) | 2000-01-20 |
DE69940157D1 (en) | 2009-02-05 |
DE69941454D1 (en) | 2009-11-05 |
US20040009183A1 (en) | 2004-01-15 |
CA2339355A1 (en) | 2000-01-20 |
WO2000002523A2 (en) | 2000-01-20 |
EP1097213B1 (en) | 2009-09-23 |
ATE443768T1 (en) | 2009-10-15 |
WO2000002523A3 (en) | 2000-11-23 |
WO2000002522A9 (en) | 2001-04-05 |
AU5667399A (en) | 2000-02-01 |
US7374931B2 (en) | 2008-05-20 |
AU758019B2 (en) | 2003-03-13 |
EP1097212A2 (en) | 2001-05-09 |
AU5542699A (en) | 2000-02-01 |
ATE418612T1 (en) | 2009-01-15 |
WO2000002523A9 (en) | 2000-07-27 |
AU761021B2 (en) | 2003-05-29 |
US6632640B1 (en) | 2003-10-14 |
WO2000002522A2 (en) | 2000-01-20 |
EP1097212B1 (en) | 2008-12-24 |
EP1097213A2 (en) | 2001-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000002522A3 (en) | Anthrax vaccine | |
WO1999051748A3 (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
AU3447497A (en) | Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2 | |
AU2002345653A1 (en) | Diagnostic device, system and method | |
MXPA03002680A (en) | Short range spread-spectrum radiolocation system and method. | |
HK1040026A1 (en) | Flow identifying device, flow processing device, flow identifying method, and flow processing method. | |
WO1998016646A3 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
EP1071451A4 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
ZA956797B (en) | Method for preparing influenza virus, antigens obtained and the applications. | |
WO2001098460A3 (en) | Fusion proteins of mycobacterium tuberculosis | |
WO1998013500A3 (en) | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines | |
ZA971663B (en) | Porcine reproductive and respiratory syndrome vaccine. | |
AU5906699A (en) | (neisseria spp.) polypeptide, nucleic acid sequence and uses thereof | |
ZA969402B (en) | Novel oligopeptides, the preparation and use thereof. | |
AU2002212049A1 (en) | Novel silicone material, its preparation method and the use thereof | |
AU3617401A (en) | Tying clips, pliers and method for the use thereof | |
AU2002303646A1 (en) | Vectors having replication, immunogenicity and/or pathogenicity under stress promoter regulation and use thereof | |
AU2002342949A1 (en) | Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other | |
ZA9610510B (en) | Novel peptides, the preparation and use thereof. | |
ZA971999B (en) | Disubstituted glutarimide, method for its preparation and its use. | |
GB9824569D0 (en) | Virulence gene and protein,and their use | |
AU8339898A (en) | Sperm specific antigens 4.1 and 6.7, dna encoding them and contraceptive vaccines comprising said sperm antigens | |
GB0003736D0 (en) | Virulence gene and protein, an their use | |
AU2002352638A1 (en) | Tlp antigen extract, its preparation and diagnostic applications thereof | |
WO1997041252A3 (en) | Dna, rna and a protein useful for detection of a mycobacterial infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2339355 Country of ref document: CA Kind code of ref document: A Ref document number: 2339355 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999941953 Country of ref document: EP Ref document number: 55426/99 Country of ref document: AU |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; PAGES 1-4, SEQUENCE LISTING, REPLACED BY NEW PAGES 1-8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWP | Wipo information: published in national office |
Ref document number: 1999941953 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 55426/99 Country of ref document: AU |